Thus, significant revenue is years away, and actual profit some years beyond that, since HGS will spend heavily on research during that time. Those companies' bottles should sport enormous skulls and crossbones, and maybe even a Mr. Yuck. If you're a longtime Rule Breaker investor, you know this already. If you're dropping by for the first time or so, please check out the Rule Breaker resource links to the right. Hey, it's dangerous out there.
Today there's a shortage of organs for increasingly successful transplants.
I borrowed that definition from tissue engineering leaders Joseph Vacanti and Robert Langer, professors at Harvard and MIT, respectively. They are fast friends in a world famed for fierce rivalries and back-stabbing. Their work and graduate students have seeded the field worldwide. This form of therapy accounts for a large part of healthcare resources. The liver, heart, kidney, and breast are more complex organs and tougher.